The JTB Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population optimized for functional studies of JTB (Jumping Translocation Breakpoint). This product consists of A-549 cells carrying a heterogeneous pool of JTB gene disruptions introduced by CRISPR/Cas9, creating a loss-of-function model that preserves the genetic diversity of a non-clonal knockout. Researchers can use this polyclonal system to probe JTB-mediated mitochondrial processes in a setting that mimics intratumoral heterogeneity. The population is provided with validated disruption of JTB, ensuring consistent experimental performance.
The A-549 cell line, isolated from a 58-year-old Caucasian male with lung adenocarcinoma, is a widely used model of alveolar type II epithelium. These adherent epithelial cells exhibit metabolic and apoptotic features characteristic of non-small cell lung cancer, making them a relevant host for studying JTB function in a tumor context. A-549 cells retain key oncogenic signaling pathways and are extensively employed in cancer biology research, including investigations of mitochondrial dysfunction and therapy resistance.
JTB encodes a critical component of the mitochondrial contact site and cristae organizing system (MICOS), directly interacting with IMMT (mitofilin/MIC60), MIC19, MIC25, and OPA1. Within the MICOS complex, JTB maintains cristae junction architecture and mitochondrial ultrastructure. Disruption of JTB leads to BAX/BAK-mediated cytochrome c release, mitochondrial membrane potential collapse, and reduced ATP synthesis, thereby sensitizing cells to intrinsic apoptosis. Upstream signals, including potential MYC regulation, tie JTB to proliferation control. This positions JTB as a central regulator linking mitochondrial dynamics, apoptosis, and cancer cell metabolism.
In A-549 lung adenocarcinoma cells, knockout of JTB disrupts MICOS-dependent cristae organization, offering a model to study how mitochondrial structural changes influence tumor metabolism and apoptotic sensitivity. JTB loss can enhance vulnerability to apoptosis by facilitating cytochrome c mobilization, a phenotype relevant for understanding chemosensitivity and metabolic reprogramming in non-small cell lung cancer. This polyclonal knockout system enables dissection of the interplay between mitochondrial architecture and cell death signaling in a cancer background.
Applications include transmission electron microscopy for cristae morphology, Seahorse respirometry for metabolic profiling, and Annexin V staining for apoptosis. Western blotting for MICOS components and cytochrome c, as well as immunofluorescence for mitochondrial markers, further enable mechanistic studies. These JTB knockout cells are valuable for research on mitochondrial dynamics, apoptosis pathways, and metabolic alterations in lung adenocarcinoma. For additional information or technical support, contact Ascent Research.
